What does it really cost to make GRAS notification mandatory?

The FDA’s proposed GRAS overhaul promises greater transparency, but the headline numbers may not tell the whole story. Beyond the administrative cost of filing a notification are potentially much larger expenses tied to toxicology, exposure assessments, expert review, regulatory support, and delays.

In Episode 135 of the Orange Pill Podcast, we unpack the economics behind the proposal, the difference between paying for the “envelope” and the scientific “dossier,” and why smaller ingredient innovators could feel the impact most.

The question isn’t whether transparency has value—it’s what that transparency will ultimately cost.